| Literature DB >> 30622423 |
Wen Li1,2, Ming Xi Jia1, Jing Deng1,2,3, Jian Hui Wang4, Qin Lu Lin2, Jian Xin Tang1, Xiao Xi Zeng1, Fang Cai5, Liang Ma1, Wei Su1, Xue Ying Liu1, Cun Liu1, Sha Sha Wang1, Li Yi Zhou1,2.
Abstract
MicroRNAs (miRNAs) may regulate diverse biological processes and play an important role in cancer. And MiRNAs have been proposed as a useful tool for lung cancer diagnosis and therapeutics in cancer. The purpose of the present study was to investigate the association among the expression level of mature miR-200b-5p in peripheral blood and the risk of lung cancer and clinic pathological characteristics. This case-control study included 24 patients with lung cancer and 12 healthy controls. MiR-200b expression was deleted using real-time PCR. and the miR-200b expression of normal controls was significantly higher than that in lung cancer patients (1732.13 pg/mL vs 881.67 pg/mL, P < 0.05), no difference with age, sex, tissue type and clinical stage of lung cancer patients (P > 0.05). Furthermore, miR-200b expression level fluctuated with tumor progression in lung cancer, and there was highly significant for clinical stage II compared with the clinical stage III (P < 0.05). In addition, the down-regulation of miR-200b showed a highly discriminative receiver operating characteristic (ROC) curve profile, clearly distinguishing cancer patients from cancer-free subjects with an area under the ROC curve (AUROC) of 0.87. The detection of miR-200b expression yielded 83.30% sensitivity and 100.00% specificity in the diagnosis of lung cancer. Therefore, these findings suggested that miR-200b may be used as a marker for the detection and diagnosis of lung cancer in peripheral blood.Entities:
Keywords: Lung cancer; MiR-200b; Molecular markers; Prognosis
Year: 2018 PMID: 30622423 PMCID: PMC6319082 DOI: 10.1016/j.sjbs.2018.08.023
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 1319-562X Impact factor: 4.219